Literature DB >> 2867355

Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland.

H Peltola, V Karanko, T Kurki, V Hukkanen, M Virtanen, K Penttinen, M Nissinen, O P Heinonen.   

Abstract

An immunisation programme to eliminate measles, mumps, and rubella from Finland within 10 years was started in November, 1982. A combined live vaccine is being given twice, at the ages of 14-18 months and 6 years, but at the beginning of the project children between these age limits are also being immunised. Because vaccinations are traditionally done by the public health nurses, special attention was paid to their motivation. 2.5 years after the launch of the project, 80.9% of the target children had been vaccinated. The incidence of measles has fallen by 93% and that of mumps by 87% compared with a normal prevaccination year (1982). A similar fall in incidence was seen for rubella, but only in the vaccinated age groups. Although elimination of measles, mumps, and rubella is not likely to be achieved with the present vaccination coverage, a drastic fall in the incidence of all three target diseases has occurred already. Every effort is being made to improve the coverage and thus to achieve the ultimate goal of the project.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2867355     DOI: 10.1016/s0140-6736(86)92270-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

1.  Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine.

Authors:  M Paunio; H Peltola; M Valle; I Davidkin; M Virtanen; O P Heinonen
Journal:  J Epidemiol Community Health       Date:  1999-03       Impact factor: 3.710

Review 2.  Pharmacoeconomics of immunisation: a review.

Authors:  R van den Oever; D de Graeve; B Hepp; A Stroobant; D Walckiers; V Van Casteren; F Van Loock; G Ducoffre; J Dewatripont; P Jacques
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

3.  Measles, mumps, and rubella vaccine: time for a two stage policy?

Authors:  H Carter; D Gorman
Journal:  BMJ       Date:  1992-03-07

Review 4.  Rational use of measles, mumps and rubella (MMR) vaccine.

Authors:  H Carter; H Campbell
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Incidence of mumps.

Authors:  S R Palmer; A Biffin
Journal:  J R Coll Gen Pract       Date:  1989-01

6.  Immunisation before school entry: should there be a law?

Authors:  N D Noah
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-16

7.  The HLA-DR phenotype modulates the humoral immune response to enterovirus antigens.

Authors:  K Sadeharju; M Knip; M Hiltunen; H K Akerblom; H Hyöty
Journal:  Diabetologia       Date:  2003-07-05       Impact factor: 10.122

8.  Measles in developing countries. Part II. The predicted impact of mass vaccination.

Authors:  A R McLean; R M Anderson
Journal:  Epidemiol Infect       Date:  1988-06       Impact factor: 2.451

9.  Decline of mumps antibodies in type 1 (insulin-dependent) diabetic children and a plateau in the rising incidence of type 1 diabetes after introduction of the mumps-measles-rubella vaccine in Finland. Childhood Diabetes in Finland Study Group.

Authors:  H Hyöty; M Hiltunen; A Reunanen; P Leinikki; T Vesikari; R Lounamaa; J Tuomilehto; H K Akerblom
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

10.  Duration of the immune response to MMR vaccine in children of two age-different groups.

Authors:  S Li Volti; G Giammanco-Bilancia; M Grassi; R Garozzo; R Gluck; G Giammanco
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.